Abstract
Objective: To explore the clinical diagnostic value of dual-energy CT (DECT) imaging technology in patients with gout. Methods: A total of 83 suspected gout patients admitted from June 2019 to December 2020 were selected. DECT and gold standard examinations (polarized light microscopy of joint fluid) were performed on all patients. Results: The sensitivity, specificity, negative predictive value, and positive predictive value of DECT in diagnosing gout were 92.31%, 83.33%, 75%, and 95.24%, respectively. The kappa value was 0.73, and the area under the ROC curve was 0.88 (P < 0.01). DECT detected 4.40 times more urate crystal deposits than physical examinations. Detection rates were significantly higher in the chronic intermittent period compared to the acute phase. Conclusion: DECT imaging technology can accurately display urate deposition, demonstrating high clinical reliability.
Introduction
Gout is a painful inflammatory condition caused by the deposition of monosodium urate (MSU) crystals in joints. Traditionally, the "gold standard" for diagnosis is synovial fluid aspiration—an invasive and painful procedure that involves extracting joint fluid to identify crystals under a polarized light microscope. This method can be technically challenging in small joints or during early disease stages. While standard imaging like X-rays or ultrasound is available, they often lack the sensitivity to detect early-stage gout or the specificity to distinguish MSU crystals from other calcifications. This study evaluates whether Dual-Energy CT (DECT) can provide a reliable, non-invasive "virtual biopsy" for clinical diagnosis.
Methods
The researchers conducted a clinical study of 83 patients (74 males, 9 females) with suspected gout. The core technology utilized was a Dual-Energy CT scanner (SOMATOM Definition Flash). Unlike conventional CT, which uses a single X-ray spectrum, DECT uses two different energy outputs simultaneously. This allows the system to differentiate materials based on their specific energy attenuation characteristics. A three-material decomposition algorithm was used to color-code the results: blue for bone cortex, purple for cancellous bone, and green for urate crystals. These results were compared against needle aspiration results and clinical physical examinations.
Results: Diagnostic Performance
The study demonstrated that DECT is a highly reliable diagnostic tool with a sensitivity of 92.31% and a positive predictive value of 95.24%. The overall diagnostic performance, represented by an Area Under the ROC Curve (AUC) of 0.88, indicates strong clinical utility.
As shown in the table above, DECT correctly identified 60 true positive cases out of 65 confirmed patients, with only 3 false positives among the 18 non-patients. The resulting Kappa value of 0.73 indicates substantial agreement with the gold standard.
Clinical Insights and Phase Sensitivity
One of the most significant findings was DECT's superior detection capability compared to physical exams. DECT identified 502 urate crystal deposits, whereas clinicians identified only 114 sites through history and physical examinations, suggesting that DECT can detect "subclinical" gout before it becomes palpable as tophi.
Furthermore, the technology's effectiveness varies by disease stage. The detection rate of both urate crystals and bone destruction was significantly higher in patients during the chronic intermittent period than in those in the acute phase.
This phase-dependent sensitivity (94.6% in chronic vs. 71.4% in acute) likely occurs because crystal deposits grow larger and more stable over time, making them easier for the algorithm to distinguish from surrounding tissue. DECT also proved effective at visualizing bone erosion, which was present in 67.6% of chronic patients compared to only 32.1% of acute patients.
Conclusion and Limitations
DECT imaging technology offers a powerful, non-invasive alternative to joint punctures, providing clear visualization of urate deposition. However, the study notes that radiologists must manually filter out artifacts (such as vascular calcification or thick skin) that can appear as false positives. Future research with larger sample sizes and longitudinal data is needed to track changes in crystal volume over time and further validate DECT's role in monitoring treatment efficacy.
Summary updated